Dear Editor,On July 25,2024,an Oncologic Drugs Advisory Committee meeting was held to discuss the design of the AEGEAN trial,which evaluated the perioperative use of durvalumab for resectable non-small cell lung cance...Dear Editor,On July 25,2024,an Oncologic Drugs Advisory Committee meeting was held to discuss the design of the AEGEAN trial,which evaluated the perioperative use of durvalumab for resectable non-small cell lung cancer(NSCLC)[1].The Food and Drug Administration(FDA)stated that the two-arm trial was not designed to isolate contributions of neoadjuvant and adjuvant phases.Since the clinical benefit of adjuvant durvalumab remains uncertain,this limitation raises concerns about potential over-treatment.展开更多
基金supported by the Beijing Nova Program(20230484277)and the National Natural Science Foundation of China(82303955).
文摘Dear Editor,On July 25,2024,an Oncologic Drugs Advisory Committee meeting was held to discuss the design of the AEGEAN trial,which evaluated the perioperative use of durvalumab for resectable non-small cell lung cancer(NSCLC)[1].The Food and Drug Administration(FDA)stated that the two-arm trial was not designed to isolate contributions of neoadjuvant and adjuvant phases.Since the clinical benefit of adjuvant durvalumab remains uncertain,this limitation raises concerns about potential over-treatment.
